Despite Esbriet Sales Nearly Tripling, InterMune's Loss Widens by 7%

Esbriet sales soar overseas for InterMune, but are more than offset by higher R&D and SG&A expenses tied to a potential U.S. launch of the drug.

May 1, 2014 at 7:49PM

Momentum is building for biopharmaceutical mid-cap InterMune (NASDAQ:ITMN), which reported strong year-over-year sales gains in the first quarter for lead drug Esbriet, a treatment for idiopathic pulmonary fibrosis.

For the quarter, InterMune reported a 188% year-over-year increase in Esbriet sales, to $30.3 million from $10.5 million in the year-ago period. Furthermore, this was an 18% sequential increase from the $25.7 million in revenue recorded in the fourth quarter, as InterMune notes that its IPF therapy is now launched and reimbursable in 14 of its 15 top-priority European markets.

Investors need to know that InterMune is planning to resubmit its application for pirfenidone, the scientific name for Esbriet, with the Food and Drug Administration in the U.S. early in the third-quarter. With its new drug application being a class 2 resubmission, it anticipates a review process of just six months. If all goes well, InterMune anticipates a drug launch in the U.S. during the second quarter.

Research and development expenses rose 24% during the quarter, to $32.1 million, reflecting the higher costs associated with its ASCEND phase 3 trial and activities related to its preparation for a new drug application in the U.S. Selling, general, and administrative expenses also jumped 48%, to $44.3 million, which InterMune primarily attributed to pre-launch preparations in the U.S.

Net loss for the quarter widened 7%, to $53.6 million, from the year-prior period, but fell on an EPS basis due to more shares outstanding, to $0.59 from $0.64 in Q1 2013.

Looking ahead, InterMune boosted its full-year revenue forecast for Esbriet to a range of $130 million to $140 million, an 85%-100% increase from the $70.3 million in reported sales in 2013. InterMune kept its R&D and SG&A forecasts unchanged at $110 million-$120 million and $210 million-$225 million, respectively.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information